The Food and Drug Administration on Tuesday approved Sanofi and Regeneron Pharmaceutical’s drug Dupixent as a treatment for moderate to severe eczema. Here are four things to know. 1. Dupixent, which ...

WASHINGTON — The first new type of drug in decades to treat the troubling skin disease eczema moved a step closer to market last week as the government’s scientific advisors unanimously declared ...

Eli Lilly announced on Friday safety and efficacy results from two separate late-stage studies testing its approved drugs for ...

The Food and Drug Administration granted priority review status to dupilumab, an injectable antibody drug used to treat atopic dermatitis, or eczema. The drug, developed by Paris-based Sanofi and ...

June 24 (Reuters) - Nektar Therapeutics (NKTR.O), opens new tab said on Tuesday its lead drug candidate met the main goal of a mid-stage study testing the drug in eczema patients, sending its shares ...

Sanofi said its amlitelimab experimental drug met all main goals in a late-stage clinical trial with eczema patients. The French pharmaceutical company said Thursday that amlitelimab showed efficacy ...

Amgen AMGN announced positive results from two clinical studies, IGNITE and SHUTTLE, which are part of the phase III ROCKET program that is evaluating the investigational anti-OX40 therapy ...

A prescription cream and an ointment that millions of Americans use to control eczema should carry strong warnings to alert consumers that the drugs may increase the risk of some forms of cancer, ...

Shares of Apogee TherapeuticsAPGE have gained 34% over the past two days as the small biotech looks to take on Regeneron PharmaceuticalsREGN and SanofiSNY in eczema treatment. The bonanza on Apogee ...

(Reuters) - Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema treatment, Dupixent, and announced a dividend and stock buyback ...